FDA Accepts uniQure Huntington’s Disease Therapy Application for Priority Review
The FDA accepted uniQure’s biologics license application for ifezuntirgene inilparvovec and granted it priority review for Huntington’s disease.
Related stories
Hangzhou SDIC Microelectronics and Controlling Shareholder Probed by Regulator
The company says it and its controlling shareholder are under investigation over suspected information disclosure violations.
L impact | REGULATION | Nov 02, 2026, 01:41 PM UTC
FDA Places Bright Minds Biosciences Seizure Drug Application on Partial Hold
Bright Minds Biosciences said the FDA placed its drug application and planned trial for a seizure treatment on partial clinical hold following a review. The stock fell 36% to $35 i
M impact | REGULATION | Nov 02, 2026, 01:19 PM UTC
NRx Pharmaceuticals Receives FDA Approval for Preservative-Free Ketamine
NRx Pharmaceuticals said the FDA approved its preservative-free ketamine application ahead of the agency’s November 10 goal date.
M impact | REGULATION | Nov 02, 2026, 01:13 PM UTC
UniQure Says FDA Accepts Application for Huntington’s Gene Therapy
UniQure said the FDA accepted an application for its potential Huntington’s disease gene therapy.
L impact | REGULATION | Nov 02, 2026, 01:06 PM UTC
Catheter Precision Announces FDA 510(k) Clearance for VIVO System
The clearance enables use of the VIVO system in a broader patient population.
L impact | REGULATION | Nov 02, 2026, 01:05 PM UTC
Lupin Receives U.S. FDA Approval for Amifampridine Tablets
M impact | REGULATION | Nov 02, 2026, 12:34 PM UTC